Melissa Abel
Public Communications Contact at 89BIO, INC.
Profile
Melissa Abel is currently working as the VP-Commercial Strategy & Communications at 89bio, Inc. Previously, she held the position of Vice President-Commercial Strategy at Five Prime Therapeutics, Inc. from 2016 to 2020, and at Concentric Analgesics, Inc. from 2016 to 2020.
Prior to that, Melissa worked at Smithkline Beecham from 1995 to 1999 in Sales & Marketing.
Melissa holds an MBA from Emory University and an undergraduate degree from The University of Chicago.
Melissa Abel active positions
| Companies | Position | Start |
|---|---|---|
| 89BIO, INC. | Public Communications Contact | - |
Former positions of Melissa Abel
| Companies | Position | End |
|---|---|---|
| FIVE PRIME THERAPEUTICS, INC. | Corporate Officer/Principal | 2019-12-31 |
Concentric Analgesics, Inc.
 Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 2019-12-31 |
| Smithkline Beecham | Sales & Marketing | 1999-01-01 |
Training of Melissa Abel
| Emory University | Masters Business Admin |
| The University of Chicago | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| 89BIO, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
| Smithkline Beecham | |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | Technology Services |
- Stock Market
- Insiders
- Melissa Abel
